References
1. Khan AN, Jones C, Macdonald S. Bronchopulmonary aspergillosis: a review. Curr Probl Diagn Radiol2003;32:156–168.
2. Soubani AO, Chandrasekar PH. The clinical spectrum of pulmonary aspergillosis. Chest2002;121:1988–1999.
3. Young RC, Bennett JE, Vogel CL, et al. Aspergillosis. The spectrum of disease in 98 patients.Medicine (Baltimore) 1970;49:147–173.
4. Kang EY, Kim DH, Woo OH, et al. Pulmonary aspergillosis in immunocompetent hosts without underlying lesions of the lung: radiologic and pathologic findings. AJR Am J Roentgerol 2002;178:1395–1399.
5. Kahn FW, Jones JM, England DM. The role of bronchoalveolar lavage in the diagnosis of invasive pulmonary aspergillosis. Am J Clin Pathol 1986;86:518–523.
6. Gerson SL, Talbot GH, Hurwitz S, et al. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med 1984;100:345–351.
7. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) 2000;79:250–260.
8. Parameswaran K, Joshi M, Ravindran P. Unusual radiological presentation and rapid fatal progression of invasive pulmonary aspergillosis in an immunocompetent young patient. Respirology 1999;4:287–290.
9. Ko JP, Kim DH, Shepard JA.. Pulmonary aspergillosis in an immunocompetent patient. J Thorax Imaging 2002;17:70–73.
10. Ali ZA, Ali AA, Tempest ME, et al. Invasive pulmonary aspergillosis complicating chronic obstructive pulmonary disease in an immunocompetent patient. J Postgrad Med 2003;49:78–80.
11. Blum J, Reed JC, Pizzo SV, et al. Miliary aspergillosis associated with alcoholism. AJR Am J Roentgenol 1978;131:707–709.
12. Brattsand R, Linden M. Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies. Aliment Pharmacol Ther 1996;10 (Suppl 2):81–90.
13. Agusti C, Rano A, Filella X, et al. Pulmonary infiltrates in patients receiving long-term glucocorticoid treatment: etiology, prognostic factors, and associated inflammatory response. Chest 2003;123:488–498.
14. Palmer LB, Greenberg HE, Schiff MJ. Corticosteroid treatment as a risk factor for invasive aspergillosis in patients with lung disease. Thorax 1991;46:15–20.
15. Tankanow L, Eichenhorn MS. Disseminated Strongyloides stercoralis and Aspergillus fumigatus presenting as diffuse interstitial pneumonitis in a steroid-dependent chronic obstructive pulmonary disease patient. Henry Ford Hospital Med J 1988;36:41–43.
16. Lake KB, Browne PM, Van Dyke JJ, et al. Fatal disseminated aspergillosis in an asthmatic patient treated with corticosteroids. Chest 1983;83:138–139.
17. Waldhorn RE, Tsou E, Kerwin DM. Invasive pulmonary aspergillosis associated with aspergilloma in sarcoidosis. South Med J 1983;76:251–253.
18. O'Brien AA, Moore DP, Keogh JA. Pulmonary berylliosis on cortico-steroid therapy, with cavitating lung lesions and aspergillomata–report on a fatal case. Postgrad Med J 1987;63:797–799.
19. Weiss LM, Thiemke WA. Disseminated Aspergillus ustus infection following cardiac surgery. Am J Clin Pathol 1983;80:408–411.
20. Boes B, Bashir R, Boes C, et al. Central nervous system aspergillosis. Analysis of 26 patients. J Neuroimaging 1994;4:123–129.
21. Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996;23:608–615.